Table 1. Overall survival time in different sialyltransferases of TCGA human ovarian cancer.
| Sialyltransferase | Overall survival time (Days) | |||
|---|---|---|---|---|
| Low expression(n=376) | High expression(n=186) | p-value | ||
| α2,3-sialylation | ST3GAL I | 1042.1±88.0 | 921.7±93.8 | 0.02 * |
| ST3GAL II | 993.2±82.1 | 1020.6±114.6 | 0.99 | |
| ST3GAL IV | 969.3±81.3 | 1068.8±116.2 | 0.28 | |
| α2,6-sialylation | ST3GAL V | 1005.1±83.1 | 996.4±111.5 | 0.38 |
| ST3GAL VI | 993.9±81.3 | 1019.1±117.1 | 0.27 | |
| ST6GAL I | 942.7±82.7 | 1122.6±110.8 | 0.15 | |
| ST6GALNAC II | 955.7±77.5 | 1096.3±126.0 | 0.39 | |
| ST6GALNAC IV | 1016.8±84.5 | 972.7±106.9 | 0.61 | |
| ST6GALNAC V | 961.0±81.0 | 1085.6±116.6 | 0.62 | |
| ST8SIA I | 1006.1±85.8 | 994.5±103.1 | 0.45 | |
| ST8SIA II | 988.0±81.6 | 1030.9±115.8 | 0.22 | |
| α2,8-sialylation | ST8SIA III | 979.6±82.6 | 1048.0±112.8 | 0.56 |
| ST8SIA IV | 1007.8±83.3 | 991.0±111.0 | 0.49 | |
| ST8SIA V | 983.2±81.9 | 1040.8±115.2 | 0.86 | |
*Kaplan Meier overall survival analysis